MétaCan
Menu
← Back to cohort
Record W2887830073 · doi:10.4212/cjhp.v50i1.2002

Current Status of the HIV Vaccine

2018· article· en· W2887830073 on OpenAlexvenueno aff
Michael Armas, Jan Sahai, George G. Zhanel

Bibliographic record

VenueThe Canadian Journal of Hospital Pharmacy · 2018
Typearticle
Languageen
FieldImmunology and Microbiology
TopicHIV Research and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsHIV vaccineVirologyMedicineHuman immunodeficiency virus (HIV)ImmunologyImmunityBiologyImmune systemVaccine trial

Abstract

fetched live from OpenAlex

ABSTRACT As the HIV pandemic continues, our best current treatments (reverse transcriptase inhibitors and protease inhibitors) only manage to slow the progression of the disease and do not represent a cure. Thus, the development of a prophylactic HIV vaccine would be of enormous benefit in controlling the HIV crisis. However, designing an HIV vaccine will require researchers to overcome many obstacles including the ability of the virus to integrate in the host genome and thus avoid immunological attach, its transmission as a free or cell-associated virus, HIV's rapid and frequent antigenic variation and the limited number of animal models available for testing. Currently, more than 20 candidate vaccines are undergoing phase I/II testing. Three main vaccine types are being developed, HIV subunit vaccines, live-virus vector vaccines and combinations of these vaccines. The combination vaccines, which induce strong and broadly reactive humoral and cell mediated immunity appear to be the best candidate vaccines. Despite the enormous advances in our understanding of the biology and immunology of HIV, it is unlikely that a vaccine will be ready for large scale use within the next 10 years. RESUME La pandemie du VIH poursuit sa course et notre arsenal therapeutique actuel (inhibiteurs de la transcriptase inverse et inhibiteurs de la protease) ne reussit qu'a ralentir la progression de cette maladie, et ne constitue malheureusement pas une cure. La mise au point de vaccins anti-VIH serait clone un avantage indeniable dans la lutte contre cette infection. Le developpement d'un tel vaccin demandera aux chercheurs de surmonter de nombreux obstacles dont la capacite qu'a le virus a s'integrer au genome hote et ainsi a eviter les defenses immunologiques, son mode de transmission libre ou a mediation cellulaire, sa variation antigenique frequente et rapide, sans compter le nombre restreint d’animaux disponibles pour l'experimentation, A l'heure actuelle, plus de 20 vaccins sont a l'essai en phase l/II. Les chercheurs ont mis au point trois principaux types de vaccins: les vaccins a sous-unite VIH, les vaccins a vecteur de virus vivant et les vaccins combinant ces deux derniers types. Les vaccins combines qui induisent une immunite humorale et cellulaire forte et etendue semblent etre les plus prometteurs. Mais malgre les progres spectaculaires dans notre comprehension de la biologie et de l'immunologie du VIH, il semble peu probable qu'un vaccin pouvant etre utilise a grande echelle puisse voir le jour d'ici les dix prochaines annees.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.019
Threshold uncertainty score0.064

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0030.004
Open science0.0020.001
Research integrity0.0050.004
Insufficient payload (model declined to judge)0.0190.006

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.298
Teacher spread0.280 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueThe Canadian Journal of Hospital Pharmacy→Same topicHIV Research and Treatment→French-language works237,207→